AI assistant
STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2025
Sep 8, 2025
62616_rns_2025-09-08_6f2d0701-b449-4949-863a-d78e45c07c59.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [144 x 47] intentionally omitted <==
September 8, 2025
BSE Limited The National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex Dalal Street, Mumbai – 400 001 Bandra (E) Mumbai - 400 051 Scrip code: 532531 Scrip code: STAR
Dear Madam/ Sir,
Sub: Press Release
Please find attached Press Release issued by the Company titled:
“Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market”
Thanks & Regards,
For Strides Pharma Science Limited,
MANJULA Digitally signed by MANJULA R R Date: 2025.09.08 18:14:29 +05'30'
Manjula Ramamurthy Company Secretary ICSI Membership No. A30515
Encl. As above
Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India Tel: +91-80-6784 0000 Fax: +91 80 6784 0700 Regd Off: ‘ Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India Tel: +91-22-2789 2924/ 3199 [email protected]; www.strides.com
==> picture [100 x 39] intentionally omitted <==
==> picture [81 x 28] intentionally omitted <==
Strides Enters into a Strategic Product Development Partnership with Kenox to Expand Nasal Spray Portfolio for the US Market
-
Partnership strengthens Strides’ pipeline of nasal spray products across diverse therapeutic areas
-
Kenox to provide formulation and development expertise in Orally Inhaled and Nasal Drug Products (OINDPs)
-
Collaboration aims to accelerate affordable, high-quality medicines for patients in the US
Bangalore, India, September 8, 2025: Strides Pharma Science Ltd ( BSE: 532531, NSE: STAR ), today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore has entered into a strategic product development partnership with Kenox Pharmaceuticals Inc. (“Kenox”), a fastgrowing contract development and manufacturing company specializing in Orally Inhaled and Nasal Drug Products (OINDPs).
Under the terms of the agreement, Strides will collaborate with Kenox on the development and filing of multiple nasal spray products for the US market across diverse therapeutic indications. Specific product details remain confidential at this stage.
“We are delighted to announce this partnership with Kenox, a company that brings deep technical expertise in the OINDP space. Nasal sprays have consistently been highlighted as a key focus area for Strides, and this collaboration further builds on the solid progress we have already made in this domain. With continued investments in the capabilities and capacities at our US facility, these products are a natural fit within our strategy to expand into our nasal spray technology domain. Kenox’s formulation and development strengths perfectly complement our manufacturing and go-to-market strengths allowing us to accelerate our range of nasal spray offerings in the US market.” said Aditya Kumar, Executive Director Business Development, Strides Pharma Science Limited.
Dr. Sitaram Velaga, Founder, President and CEO of Kenox Pharmaceuticals Inc. , added:
“Our strategic partnership with Strides is a significant milestone for Kenox. This collaboration validates our expertise in the OINDP space and will allow us to leverage our capabilities to bring important drug products to global patients at an affordable price.”
The partnership will advance a pipeline of nasal spray products for the US market, combining Strides’ commercial strengths with Kenox’s OINDP expertise to deliver affordable, high-quality therapies to patients.
About Strides
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries. Additional information is available at the Company’s website at www.strides.com.
About Kenox
Established in 2018 and based in greater Princeton, NJ, Kenox specializes in pharmaceutical aerosol product development, including soft mist inhalers (SMIs), dry powder inhalers (DPIs), nebulizers, and nasal sprays. As a contract development organization, Kenox offers a wealth of expertise in formulation design, compounding, fill and finish, and testing in compliance with compendial monographs.
For further information, please contact:
| Institutional Investors Vikesh Kumar Group CFO Email:[email protected] Saurabh Ambaselkar Investor Relations - +91 99609 31220 Email:[email protected] Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560076 |
Corporate Communication Pallavi Panchmatia:+91 80 6784 0193 Email: [email protected] Janhavi Bellare: +91 93228 54508 [email protected] Talal Syed: +91 99876 19679 [email protected] |
|
|---|---|---|
Kenox Media/Investor Contact
Sitaram Velaga
Email: [email protected]